Marker Therapeutics, Inc. (MRKR)

Marker Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	17.59	19.19	15.11	11.78	42.35	21.35
Cash & Short-Term Investments	17.59	19.19	15.11	11.78	42.35	21.35
Cash Growth	95.45%	27.01%	28.26%	-72.18%	98.34%	-51.37%
Other Receivables	1.67	2.35	1.03	2.4	0	1
Total Trade Receivables	1.67	2.35	1.03	2.4	0	1
Other Current Assets	2.48	0.48	0.99	2.44	3.63	2.06
Total Current Assets	21.73	22.02	17.13	16.62	45.98	24.41
Net Property, Plant & Equipment	-	-	-	-	22.15	21.2
Other Long-Term Assets	-	-	-	17.8	-	-
Total Assets	21.73	22.02	17.13	34.42	68.14	45.61
Accounts Payable	1.66	1.75	1.75	2.52	11.13	6.01
Current Portion of Leases	-	-	-	-	0.62	0.39
Unearned Revenue	1.35	-	-	-	1.15	-
Other Current Liabilities	0.33	1.71	1.33	5.26	-	-
Total Current Liabilities	3.35	3.46	3.07	7.78	12.9	6.4
Long-Term Leases	-	-	-	-	11.25	11.87
Other Long-Term Liabilities	-	-	-	7.04	-	-
Total Long-Term Liabilities	-	-	-	7.04	11.25	11.87
Total Liabilities	3.35	3.46	3.07	14.82	24.15	18.27
Common Stock	0.02	0.01	0.01	0.01	0.01	0.05
Additional Paid-in Capital	475.85	465.56	450.33	447.64	442.1	383.53
Retained Earnings	-457.48	-447.02	-436.29	-428.05	-398.12	-356.24
Shareholders' Equity	18.39	18.56	14.05	19.6	43.99	27.34
Total Liabilities & Equity	21.73	22.02	17.13	34.42	68.14	45.61
Total Debt	-	0	0	0	11.87	12.26
Net Cash (Debt)	17.59	19.19	15.11	11.78	30.48	9.1
Net Cash Growth	-8.35%	27.01%	28.26%	-61.35%	235.15%	-79.05%
Net Cash Per Share	1.38	2.14	1.72	1.41	3.98	1.93
Book Value	18.39	18.56	14.05	19.6	43.99	27.34
Book Value Per Share	1.44	2.07	1.60	2.35	5.75	5.81
Tangible Book Value	18.39	18.56	14.05	19.6	43.99	27.34
Tangible Book Value Per Share	1.44	2.07	1.60	2.35	5.75	5.81

Updated Sep 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q